Video

Dr. Wong on the Potential Role of Venetoclax in Relapsed/Refractory AL Amyloidosis

Author(s):

Sandy Wong, MD

In Partnership With:

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the potential role of venetoclax (Venclexta) in relapsed/refractory light chain (AL) amyloidosis.

Many treatment options are available for patients with relapsed/refractory AL amyloidosis, Wong says. However, some agents are associated with increased toxicity compared with others.

Many of these drugs were taken from the multiple myeloma paradigm, explains Wong. However, treatment-related toxicities may be more significant in AL amyloidosis versus multiple myeloma as patients with AL amyloidosis tend to be frail with multi-organ damage.

The BCL-2 inhibitor venetoclax is approved in chronic lymphocytic lymphoma and acute myeloid leukemia, Wong says. Additionally, the agent is under investigation in multiple myeloma, specifically for patients with translocation(11;14).

About half of patients with AL amyloidosis present with t(11;14) at diagnosis. As such, venetoclax could be a viable treatment option for this subgroup of patients, concludes Wong.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center
November 21st 2024

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL